Avidity Biosciences Inc’s recent filing unveils that its Chief Human Resources Officer McCarthy Teresa unloaded Company’s shares for reported $1.03 million on Nov 18 ’24. In the deal valued at $41.14 per share,25,000 shares were sold. As a result of this transaction, McCarthy Teresa now holds 94,018 shares worth roughly $3.46 million.
Then, LEVIN ARTHUR A sold 3,323 shares, generating $139,973 in total proceeds. Upon selling the shares at $42.12, the Director now owns 14,830 shares.
Before that, MacLean Michael F sold 106,319 shares. Avidity Biosciences Inc shares valued at $4,843,979 were divested by the Chief Financial Officer at a price of $45.56 per share. As a result of the transaction, MacLean Michael F now holds 94,093 shares, worth roughly $3.47 million.
RBC Capital Mkts initiated its Avidity Biosciences Inc [RNA] rating to an Outperform in a research note published on November 26, 2024; the price target was $67. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late September with a ‘”a Buy”‘ rating. Barclays began covering RNA with “an Overweight” recommendation on August 28, 2024. BofA Securities started covering the stock on May 03, 2024. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Monday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -3.71% to $36.85. Over the last five days, the stock has lost -10.77%. Avidity Biosciences Inc shares have risen nearly 307.18% since the year began. Nevertheless, the stocks have risen 357.76% over the past one year. While a 52-week high of $56.00 was reached on 11/13/24, a 52-week low of $6.79 was recorded on 01/02/24. SMA at 50 days reached $44.81, while 200 days put it at $36.48.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 35.24, which if violated will result in even more drops to 33.63. On the upside, there is a resistance level at 38.58. A further resistance level may holdings at 40.31. The Relative Strength Index (RSI) on the 14-day chart is 35.41, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.93, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.97%. Stochastics %K at 11.60% indicates the stock is a buying.
How much short interest is there in Avidity Biosciences Inc?
A steep rise in short interest was recorded in Avidity Biosciences Inc stocks on 2024-11-15, dropping by -0.37 million shares to a total of 14.52 million shares. Yahoo Finance data shows the prior-month short interest on 2024-10-15 was 14.88 million shares. There was a decline of -2.53%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on March 14, 2024 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating along with a $60 price target.
